- Breast Cancer
- Cancer Control
- Diagnostics and Screening
- Gastrointestinal Oncology
- Genitourinary Cancers
- Geriatric Oncology
- Gynecological Oncology
- Head, Neck and Thyroid Cancers
- Hematological Malignancies
- Infection in Hematology
- Lung Cancer
- Neurological Oncology
- Patient Care
- Pediatric Oncology
- Platelets, Hemostasis and Thrombosis
- Red Blood Cells
- Supportive Oncology
Bone Metastases in Breast Cancer
US Oncology Review, 2005;1(1):79-82
Patients with advanced breast cancer are at high risk for developing bone metastases and ensuing skeletal complications. Since the mid 1990s, intravenous (IV) pamidronate has been the international standard of care for breast cancer patients with bone metastases. Recently, a large, randomized, phase III trial in this patient population demonstrated that 4mg zoledronic acid, a new-generation bisphosphonate, was safe and significantly reduced the overall risk of skeletal complications compared with pamidronate. Zoledronic acid has also been shown to provide consistent, durable pain reduction in these patients compared with placebo. Based on these results, zoledronic acid is rapidly becoming the new international standard for patients with bone metastases from breast cancer.
More than 200,000 women in the US are diagnosed with breast cancer each year1 and, among the approximate one-third of these patients who develop advanced disease, 65–75% will develop bone metastases.2 These patients are at high risk for skeletal complications, including pathologic fractures, spinal cord compression, and debilitating bone pain. In fact, studies have demonstrated that in the absence of bisphosphonate therapy nearly 70% of breast cancer patients with bone metastases will experience a skeletal complication within two years, with an annual incidence of approximately four events per year (see Figure 1).3,4 Moreover, breast cancer patients have a long median survival after diagnosis of bone metastases (in the range of two to three years), during which they often suffer from significant skeletal morbidity that can have a devastating effect on quality of life.2,5
Traditional options for the treatment of patients with bone metastases from advanced breast cancer include standard anti-neoplastic therapies, surgery to treat or prevent fractures, and radiotherapy to stabilize bone lesions, prevent fractures, and palliate severe bone pain. In addition, these patients often receive systemic analgesic therapy with non-steroidal anti-inflammatory drugs (NSAIDS) or opioids. Recently, bisphosphonates have emerged as the standard for the prevention of skeletal complications in breast cancer patients with bone metastases. Bisphosphonates are potent inhibitors of bone resorption and have been shown to significantly reduce the percentage of patients with skeletal complications, delay the median time to first skeletal event, reduce the need for radiotherapy, and palliate bone pain compared with placebo in randomized, controlled trials.6
- Jemal A,Tiwari R C, Murray T et al., “Cancer statistics”, CA Cancer J. Clin. (2004), 54: pp. 8–29.
- Coleman R E, “Metastatic bone disease: clinical features, pathophysiology and treatment strategies”, Cancer Treat Rev. (2001);27: pp. 165–176.
- Lipton A,Theriault R L, Hortobagyi G N et al.,“Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials”, Cancer (2000);88: pp. 1,082–1,090.
- Coleman R E,“The role of bisphosphonates in breast cancer”, The Breast (in press).
- Weinfurt K P, Castel L D, Li Y,Timbie J W, Glendenning G A, Schulman K A,“Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions”, Med. Care (2004);42: pp. 164–175.
- Coleman R E,“Bisphosphonates: clinical experience”, Oncologist (2004);9 (suppl. 4): pp. 14–27.
- Hillner B E, Ingle J N, Chlebowski R T, et al., “American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer”, [published erratum appears in J. Clin. Oncol. (2004), 22: p. 1,351], J. Clin. Oncol. (2003);21: pp. 4,042–4,057.
- Berenson J R, Hillner B E, Kyle R A et al., “American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma”, J. Clin. Oncol. (2002);20: pp. 3,719–3,736.
- Rosen L S, Gordon D, Kaminski M et al.,“Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma.A randomized, doubleblind, multicenter, comparative trial”, Cancer (2003);98: pp. 1,735–1,744.
- Kohno N, Aogi K, Minami H et al., “A randomized, double-blind, placebo-controlled phase III trial of zoledronic acid in the prevention of skeletal complications in Japanese women with bone metastases from breast cancer [abstract]”, Proc.Am. Soc. Clin. Oncol. (2004);23: 43, (abstract 668).
- Body J-J,Diel I J, Lichinitser M R et al.,“Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases”, Ann. Oncol. (2003);14: pp. 1,399–1,405.
- Paterson A H G, Powles T J, Kanis J A, McCloskey E, Hanson J, Ashley S,“Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer”, J. Clin. Oncol. (1993);11: pp. 59–65.
- Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen H T,“Oral clodronate in breast cancer patients with bone metastases: a randomized study”, J. Intern. Med. (1999);246: pp. 67–74.
- Body J J, Diel I J, Lichinitzer M et al., “Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies”,Br. J.Cancer (2004);90: pp. 1,133–1,137.
- Rosen L S, Gordon D H, Dugan W Jr et al.,“Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion”, Cancer (2004);100: pp. 36–43.
- Rosen L S, Coleman R E, Gordon D et al.,“Zoledronic acid is superior to pamidronate in patients with breast cancer and bone metastases [poster]”, Presented at: St. Gallen Oncology Conferences: Primary Therapy of Early Breast Cancer 8th International Conference; March 12–15 2003; St Gallen, Switzerland, poster 100.
- Williams G, Pazdur R,Temple R,“Assessing tumor-related signs and symptoms to support cancer drug approval”, J. Biopharm. Stat. (2004);14: pp. 5–21.
- Conte P and Guarneri V, “Safety of intravenous and oral bisphosphonates and compliance with dosing regimens”, Oncologist (2004);9 (suppl. 4): pp. 28–37.
- Lipton A,“Management of metastatic bone disease and hypercalcemia of malignancy”, Am. J. Cancer (2003);2: pp. 427–438.
- Powles T, McCloskey E, Kurkilahti M,“Oral clodronate for adjuvant treatment of operable breast cancer: results of a randomized, double-blind, placebo-controlled multicenter trial [abstract]”, Proc.Am. Soc. Clin. Oncol. (2004);23: p. 9 (abstract 528).
- Saarto T,Vehmanen L, Blomqvist C, Elomaa I, “Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients [abstract]”, Proc.Am. Soc. Clin. Oncol. (2004);23: p. 8 (abstract 527).
- Jaschke A, Bastert G, Solomayer E F, Costa S, Schuetz F, Diel I J,“Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow-a longtime follow-up [abstract]”, Proc. Am. Soc. Clin. Oncol. (2004);23: p. 9 (abstract 529).
- Hortobagyi G N,Theriault R L, Lipton A, et al.,“Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate”, J. Clin. Oncol. (1998);16: pp. 2,038–2,044.
- Theriault R L, Lipton A, Hortobagyi G N, et al.,“Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial”, Protocol 18 Aredia Breast Cancer Study Group, J. Clin. Oncol. (1999);17: pp. 846–854.
- Diel I J, Body J J, Lichinitser M R et al.,“Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer”, Eur. J. Cancer (2004);40: pp. 1,704–1,712.
- Body J-J, Diel I, Bell R et al., “Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer”, Pain (2004);111: pp. 306–312.
- Rizzoli R, “Bisphosphonates and reduction of skeletal events in patients with bone metastatic breast cancer”, Ann. Oncol. (2004);15: pp. 700–701.
- Westermann A M,“Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases”, Ann. Oncol. (2004);15: pp. 537–538.
- Andersen P K, Gill R D, “Cox’s regression model for counting processes: a large sample study”, Ann. Stat. (1982);10: pp. 1,100–1,120.
- Rosen L S, Gordon D, Kaminski M et al.,“Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial”, Cancer J. (2001);7: pp. 377–387.
- Gnant M, Hausmaninger H, Samonigg H, et al., “Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (± zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: results of a randomized multicenter trial [abstract]”, Presented at: 25th Annual San Antonio Breast Cancer Symposium; December 11–14 2002; San Antonio,Texas (abstract 12).
- Theriault R, Jakesz R, Gnant M, Gralow J,“The evolving role of bisphosphonates for the prevention of cancer treatment-induced bone loss in patients with breast cancer [abstract]”, Bone (2004);34: pp. S90–S91 (abstract 75).
- Coleman R, Rosen L, Zheng M, on behalf of the Study 010 investigators, “Zoledronic acid has long-term efficacy in reducing skeletal complications in patients with bone metastases from breast cancer [abstract]”, Presented at: 4th European Breast Cancer Conference, March 16–19 2004; Hamburg, Germany (abstract 246).